LA JOLLA PHARMACEUTICAL CO Form 8-K/A August 01, 2003

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

FORM 8-K/A

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): June 16, 2003

La Jolla Pharmaceutical Company

(Exact Name of Registrant as Specified in Charter)

Delaware (State or Other Jurisdiction of Incorporation) 0-24274 (Commission File Number) 33-0361285 (IRS Employer Identification No.)

6455 Nancy Ridge Drive, San Diego, California (Address of Principal Executive Offices) 92121 (Zip Code)

Registrant s telephone number, including area code: (858) 452-6600

TABLE OF CONTENTS

ITEM 5. OTHER EVENTS

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND

EXHIBITS.

SIGNATURES

EXHIBIT 99.1

Table of Contents

Explanatory Note: This Form 8-K/A and the related Press Release filed herewith as Exhibit 99.1 is filed to correct information in the third sentence of the fifth paragraph of the Press Release as previously filed.

ITEM 5. OTHER EVENTS

On June 16, 2003, the Company issued a press release announcing, among other matters, the health-related quality of life results from the Riquent Phase 3 trial. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.

The following exhibits are filed with this report on Form 8-K:

Exhibit Number	Description of Exhibit
99.1	Press Release
	2

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LA JOLLA PHARMACEUTICAL COMPANY

Date: August 1, 2003 By: /s/ Steven B. Engle

Steven B. Engle Chairman and Chief Executive Officer

3